Assessment of direct-acting antiviral treatment outcomes in patients with chronic hepatitis C infected with various HCV genotypes: Insights from a real-world cohort in West Bengal, India.
{"title":"Assessment of direct-acting antiviral treatment outcomes in patients with chronic hepatitis C infected with various HCV genotypes: Insights from a real-world cohort in West Bengal, India.","authors":"Supradip Dutta, Shreyasi Nath, Raina Das, Sagnik Bakshi, Moumita Majumdar, Anwesha Ghosh, Upasana Baskey, Prosanto Kumar Chowdhury, Provash Chandra Sadhukhan","doi":"10.1186/s12879-025-11565-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Background & objectives: </strong>Genomic diversity of Hepatitis C Virus (HCV), accessibility and long-term influence of Direct Acting Antiviral (DAA) treatment remain underexplored among HCV-infected chronic liver disease (CLD) patients in the real world. This retrospective study addressed the inadequacy of assessing the effectiveness of DAA and identify genotype-specific variations in treatment response in the context of HCV epidemiology. Additionally, real-world treatment challenges encountered during the COVID-19 pandemic and the transitional phase of implementing the National Viral Hepatitis Control Program (NVHCP) guidelines have also been addressed.</p><p><strong>Methods: </strong>This retrospective study included 254 CLD patients from November 2017 and February 2020 to assess the effectiveness of DAA and long-term treatment outcomes among CLD patients.</p><p><strong>Results: </strong>HCV viremia was observed in 58.26% (n = 148) patients. Patients aged 52-59 years with a history of blood transfusions exhibited a higher prevalence of active HCV infection. Two major genotypes (GT) - GT1 and GT3, and seven subtypes with few new subtypes were identified. SVR<sub>24</sub> was achieved in 89.6% of patients receiving sofosbuvir (SOF) + daclatasvir (DCV) or SOF/ledipasvir (LDV) drug regimens. For individuals who failed to reach SVR<sub>24</sub> (n = 13), a modified regimen (SOF + Velpatasvir (VEL) + ribavirin (Riba) for 6 months) was given and the success rate was 92.31%. GT-1a and GT-1b showed better treatment response, whereas GT-3b had a lower treatment response. Among 77 SVR<sub>24</sub> achieved patients, 57.14% were cirrhotic and 42.86% were non-cirrhotic at the start of the therapy.</p><p><strong>Interpretation & conclusion: </strong>This study highlights genotype-specific variations in treatment response, with GT-3b exhibiting lower treatment response which highlights the need to decipher the reasons behind treatment failure for future therapeutic management.</p>","PeriodicalId":8981,"journal":{"name":"BMC Infectious Diseases","volume":"25 1","pages":"1180"},"PeriodicalIF":3.0000,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12481875/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12879-025-11565-3","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Background & objectives: Genomic diversity of Hepatitis C Virus (HCV), accessibility and long-term influence of Direct Acting Antiviral (DAA) treatment remain underexplored among HCV-infected chronic liver disease (CLD) patients in the real world. This retrospective study addressed the inadequacy of assessing the effectiveness of DAA and identify genotype-specific variations in treatment response in the context of HCV epidemiology. Additionally, real-world treatment challenges encountered during the COVID-19 pandemic and the transitional phase of implementing the National Viral Hepatitis Control Program (NVHCP) guidelines have also been addressed.
Methods: This retrospective study included 254 CLD patients from November 2017 and February 2020 to assess the effectiveness of DAA and long-term treatment outcomes among CLD patients.
Results: HCV viremia was observed in 58.26% (n = 148) patients. Patients aged 52-59 years with a history of blood transfusions exhibited a higher prevalence of active HCV infection. Two major genotypes (GT) - GT1 and GT3, and seven subtypes with few new subtypes were identified. SVR24 was achieved in 89.6% of patients receiving sofosbuvir (SOF) + daclatasvir (DCV) or SOF/ledipasvir (LDV) drug regimens. For individuals who failed to reach SVR24 (n = 13), a modified regimen (SOF + Velpatasvir (VEL) + ribavirin (Riba) for 6 months) was given and the success rate was 92.31%. GT-1a and GT-1b showed better treatment response, whereas GT-3b had a lower treatment response. Among 77 SVR24 achieved patients, 57.14% were cirrhotic and 42.86% were non-cirrhotic at the start of the therapy.
Interpretation & conclusion: This study highlights genotype-specific variations in treatment response, with GT-3b exhibiting lower treatment response which highlights the need to decipher the reasons behind treatment failure for future therapeutic management.
期刊介绍：
BMC Infectious Diseases is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of infectious and sexually transmitted diseases in humans, as well as related molecular genetics, pathophysiology, and epidemiology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
